See All Slides - tctmd.com

Slides

Presentation TCT 2013

Do I Need Newer Generation TAVR Devices in the USA?

Presenter: Ted Feldman

October 28, 2013

Presentation TCT 2013

The Hybrid Approach IV: When to go Retrograde and to Select Septals

Presenter: Julian Strange

October 28, 2013

Presentation TCT 2013

Case #5: An Impossible Case I Succeeded that Changed my Practice

Presenter: Evald Christiansen

October 28, 2013

Presentation TCT 2013

Latest Data from SCAAR and SWEDEHEART: Can a Nationwide Registry Tease Out Important Findings Hidden from Randomized Trials?

Presenter: Bo Lagerqvist

October 28, 2013

Presentation TCT 2013

The Case for Dedicated Bifurcation Stents; Device and Regulatory Landscape; and Anticipation of the Pivotal Tryton Results

Presenter: Martin Leon

October 28, 2013

Presentation TCT 2013

IVUS Overcomes FFR Limitations in the Left Main, and We Have the Data!

Presenter: Jose de la Torre Hernandez

October 28, 2013

Presentation TCT 2013

Stents and Pharmacotherapy in STEMI: Anticipating HORIZONS-AMI II

Presenter: Gregg Stone

October 28, 2013

Presentation TCT 2013

Yes! The Pathophysiology Dictates This and the Outcomes Data Are Clear

Presenter: Maurice Sarano

October 28, 2013

Presentation TCT 2013

Not So Fast—Direct Carotid Access Flow Reversal Is Queen!

Presenter: Sumaira Macdonald

October 28, 2013

Presentation TCT 2013

Determinants and Outcomes of Acute Valve-in-Valve Therapy or Valve Embolization During TAVR: A PARTNER Substudy

Presenter: Raj Makkar

October 28, 2013

Advertisement

Slides

Do I Need Newer Generation TAVR Devices in the USA?

The Hybrid Approach IV: When to go Retrograde and to Select Septals

Case #5: An Impossible Case I Succeeded that Changed my Practice

Latest Data from SCAAR and SWEDEHEART: Can a Nationwide Registry Tease Out Important Findings Hidden from Randomized Trials?

The Case for Dedicated Bifurcation Stents; Device and Regulatory Landscape; and Anticipation of the Pivotal Tryton Results

IVUS Overcomes FFR Limitations in the Left Main, and We Have the Data!

Stents and Pharmacotherapy in STEMI: Anticipating HORIZONS-AMI II

Yes! The Pathophysiology Dictates This and the Outcomes Data Are Clear

Not So Fast—Direct Carotid Access Flow Reversal Is Queen!

Determinants and Outcomes of Acute Valve-in-Valve Therapy or Valve Embolization During TAVR: A PARTNER Substudy

Search Slides

Advertisement

Advertisement

Slides

Search Slides

Sign Up for Our Newsletter

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content